Drug Profile


Alternative Names: N-acetyl-L-leucine; V 0251

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pierre Fabre
  • Class Small molecules; Vestibular disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Dizziness; Vertigo

Most Recent Events

  • 01 Jan 2014 Discontinued - Phase-II for Vertigo in Czech Republic, Hungary, Spain, Germany, France (IV) (Email communication Pierre Fabre, September 2017)
  • 31 Dec 2007 Phase-II clinical trials in Dizziness in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top